AIM ImmunoTech Inc. (AIM) financial statements and ratios from SEC XBRL: revenue $88000.00 (TTM), net margin -15861.4%, revenue growth -48.2% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $88000.00 |
| Net Margin | -15861.4% |
| Revenue Growth (YoY) | -48.2% |
| EPS Growth (YoY) | 2680.6% |
| Price / Book | 0.49 |
| Price / Sales | 39.69 |
| Altman Z-Score | -113.90 (distress) |
| Sector P/E (Healthcare) | 21.7 |
AIM overview · AIM earnings · AIM KPIs · AIM investor relations · AIM ownership · AIM peers · AIM filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.